Instituut voor Neuropathische Pijn
English articles Research & Development Neuropathic Pain Market booming: $5.2 billion by 2018
| Neuropathic Pain Market booming: $5.2 billion by 2018 |
The market for drugs to be used for the treatment of neuropathic pain is suggested to become very significantand seems to be booming: the forcast is e doubling in 10 years time up to a dassling figure of $5.2 billion by 2018! Under the titel: Research and Markets: Forecast Insight: Neuropathic Pain - Brighter Future for Pipeline Drugs with Market to Double in Value to $5.2 Billion, a press release of Datamonitor dated Monday February 15, 2010 states.
Neuropathic Pain Market: double digit growthThe neuropathic pain market is estimated a $5.2 billion by 2018 based on the seven major markets (US, Japan, and the five major European contries, France, Germany, Italy, Spain and the UK). It is foreseen that the US will provide the greatest increase in value over this period, but bosth Japan and Europe will generate double-digit compound annual growth rates in this indication! There are some interesting suggestions in the new market report. Cymbalta less impressiveThe drug from Eli Lilly/Boehringer Ingelheim's, Cymbalta (duloxetine), will penetrate the market in a less impressive way as formerly foreseendespite a favorable meta-analysis data in February 2009 and Datamonitor downgraded the neuropathic pain forecast for Cymbalta. This might be partly also related to the fact that clinicans seem to be less impressed by Cymbalta compared to a traditional antidepressant drug, such as amitriptyline. Ralfinamide in low back pain..Datamonitor states in their report that there exsists enough medical rationale for ralfinamide's novel mechanism of action in the treatment of pain especially in neuropathic low back pain and thus Datamonitor has substantially upgraded its neuropathic pain-specific forecast of ralfinamide. Wheter clinicians will agree we have to see. Especially sinde low back pain is quite a mixed bag!
From the Centre for the study and treatment of Neuropathic Pain and Neuropathy in Soest, the NetherlandsThis site helps patients and treating physicians, neurologists, anesthesiologists and other pain specialists to find the best and most up to date research findings related to neuropathy and neuropathic pain and the treatment thereof. In our centre we are specialised in treating patients suffering from neuropathic pain and neuropathy following an Integrated Medicine concept. Part of our activities are within the field of consultation. We assist pharmaceutical companies in R&D strategies related to finding new drugs to treat neuropathic pain and neuropathy.
April 2010, Jan M. Keppel Hesselink, MD, PhD
|